Skip to Main Content

Michelle L. Hermiston


Pediatric hematologist-oncologist
Bone marrow transplant specialist
Director, Pediatric Immunotherapy Program
Runner and camper

Dr. Michelle L. Hermiston is a specialist in caring for children with blood diseases, including cancers of the blood. In research, she has a special interest in defining the underlying mechanisms in the development of lymphoid malignancies, including leukemia and lymphoma.

Hermiston earned her medical degree and a doctorate in developmental biology at Washington State University. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at UCSF before joining the faculty in 2002. She also participated in a medical scientist training program at Washington University and in the UCSF Molecular Medicine Research Fellowship Program.

Hermiston is a member of numerous professional organizations, including the American Society of Hematology and American Academy of Pediatrics.

  • Education

    Washington University , MD, 1997

  • Residencies

    UCSF, Pediatrics, 1999

  • Fellowships

    UCS, Pediatric Hematology and Oncology, 2002

  • Academic Title

    Associate Professor

Where I see patients (3)

    Decorative Caduceus

    Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

    DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.


    More about this study
    Decorative Caduceus

    Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Ly...

    Will be reported as number and percentage of patients meeting CR/CRi criteria at the end of 8 weeks of therapy


    More about this study
    Decorative Caduceus

    Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

    to assess overall response rate following chemoimmunotherapy induction therapy


    More about this study
    Decorative Caduceus

    Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemo...

    The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.


    More about this study
    Decorative Caduceus

    Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed...

    MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT), will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4...


    More about this study
    See all clinical trials

    Fetal surgery firsts

    The first open fetal surgery in the world was performed at UCSF in the early 1980s.

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.
    This provider is employed by a medical group affiliated with UCSF.